SOUTH SAN FRANCISCO, Calif., Sept. 25, 2007 (PRIME NEWSWIRE) -- Pain Therapeutics, Inc. (Nasdaq:PTIE) has been selected as one of the inaugural companies in the new NASDAQ(r) NeuroInsights(r) Neurotech Index. This new index is being launched today.
The Neurotech Index tracks the stock performance of 32 companies engaged in R&D for the brain and nervous system. In addition to meeting minimum market criteria, these companies were identified by NeuroInsights as significantly involved in the neurotechnology industry, such as treatments or diagnostics for disorders like pain, addiction, anxiety, depression, epilepsy, etc.
"We are delighted that Pain Therapeutics has been chosen for this index," said Christi Waarich, Pain Therapeutics' senior manager of investor relations. "This reflects one of our strategic goals designed to enhance the visibility of the Company in the investment community."
About Pain Therapeutics, Inc.
Pain Therapeutics is a biopharmaceutical company that develops novel drugs. We have four investigational drug candidates in clinical programs, including Remoxy(tm), Oxytrex(tm), PTI-202 and a novel radio-labeled monoclonal antibody to treat metastatic melanoma. We are also working on a new treatment for patients with hemophilia. The FDA has not yet evaluated the merits, safety or efficacy of our drug candidates. For more information, please visit www.paintrials.com.
About NeuroInsights
NeuroInsights is the world's leading neurotechnology research and advisory firm. As the neurotechnology market authority, NeuroInsights helps investors, industry and society understand and profit from the rapid growth in drugs, devices and diagnostics for the brain and nervous system. NeuroInsights provides market reports, investment information, industry events and strategic advisory services to venture funds, startups, corporations, governments and financial institutions. For more information, please visit www.neuroinsights.com.